INCB 160058
Alternative Names: INCB-100658; INCB-160058; JAK2V617FiLatest Information Update: 19 Mar 2024
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Janus kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Myeloproliferative disorders
Most Recent Events
- 15 Mar 2024 Incyte Corporation plans a phase I trial for Myeloproliferative disorders (PO, Tablet), in June 2024 (NCT06313593)
- 11 Mar 2024 Phase-I clinical trials in Myeloproliferative disorders (In volunteers) in Australia (PO) (NCT06213818)
- 13 Feb 2024 Incyte Corporation plans phase-I trial for Myeloproliferative disorders (In volunteers) in the first half of 2024 (PO, Tablet) (NCT06213818)